Conclusion: Our study suggests that 7.6% of children with IBD also ICG-001 research buy have either PSC, ASC or AIH in this cohort. Recently, there has been increasing recognition of this association in the paediatric population. We suggest that in children with IBD who have abnormal liver biochemistry, further liver specific investigations including liver biopsy and MRCP to be considered since the additional diagnosis of PSC, ASC or AIH will have therapeutic and prognostic implications.

A JACOB,1 R BHATIA2 1Department of Gastroenterology, Western Health, Victoria, Australia., 2Department of Gastroenterology, Royal Hobart Hospital, Hobart, Tasmania, Australia Context: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western populations. Currently, liver biopsy is the gold standard method for definitive diagnosis and differentiation of simple-steatosis (SS) from non-alcoholic steatohepatitis (NASH). Objective: Visfatin/nicotinamide phosphoribosyl transferase (NAMPT) is a recently discovered novel adipokine which is elevated in obesity and various other conditions. Based on its pro-inflammatory Alpelisib in vivo properties and its role in fat and glucose metabolism, we hypothesised that visfatin might be involved in the pathogenesis of NAFLD and its measurement in serum may help in differentiating SS from NASH. Design and setting: We conducted clinical

studies at a referral medical centre on 75 morbidly obese patients presenting for lap-banding surgery, 50 with well-characterized NAFLD (SS/NASH). Main outcome measures: We examined the serum NAMPT/visfatin in patients MCE with NAFLD, and compared it in the study population (SS and NASH). Results: Visfatin was significantly elevated in NASH compared to SS in univariate analysis and in models adjusted for BMI, age, and sex. In univariate analysis mean serum visfatin was 7.05 (95%CI: 6.27–7.83) ng/ml for SS and 9.79

(95%CI: 7.95–11.62) ng/ml for NASH (p value 0.003). In BMI, age and sex adjusted models, visfatin was 7.02 (95%CI: 6.26–7.79) ng/ml and 10.12 (95%CI: 8.25–12.00) ng/ml for SS and NASH respectively (p value 0.001). Conclusion: Serum visfatin is elevated in NASH and may be useful as a predictive tool and prognostic marker in NAFLD. Visfatin may be involved in the pathogenesis and progression of NAFLD. AS RAJ,1,2 GA MACDONALD,1,2 P BHAT,1,2 LM FLETCHER,1 C TRAN,3 M BLACK,1 G HOLTMANN1,2 1Princess Alexandra Hospital, Brisbane, Australia, 2School of Medicine, University of Queensland, Brisbane, Australia, 3Womens and Children’s Hospital, Adelaide, South Australia, Australia Background: Increased small intestinal mucosal permeability may drive progression of chronic liver disease. Clinical assessment of intestinal permeability is limited by lack of standardisation of methods and assessment of liver fibrosis by liver biopsy is not without risk.